Patient-derived tissue slice grafts accurately depict response of high-risk primary prostate cancer to androgen deprivation therapy

Journal of Translational Medicine

Donna M Peehl¹  Alexandre Ingels¹  Jennifer Santos¹  Stephen W Reese¹  Rosalie Nolley¹  Alan Thong¹  Hongjuan Zhao¹ 

[1] Department of Urology, Stanford University School of Medicine, Stanford, California, USA

关键词: Tumorgrafts;    Androgen deprivation therapy;    Prostate cancer;   

Others  :  826797
DOI  :  10.1186/1479-5876-11-199

 received in 2013-05-30, accepted in 2013-08-16,  发布年份 2013

【 摘 要 】

Background

Effective eradication of high-risk primary prostate cancer (HRPCa) could significantly decrease mortality from prostate cancer. However, the discovery of curative therapies for HRPCa is hampered by the lack of authentic preclinical models.

Methods

We improved upon tumorgraft models that have been shown to predict drug response in other cancer types by implanting thin, precision-cut slices of HRPCa under the renal capsule of immunodeficient mice. Tissue slice grafts (TSGs) from 6 cases of HRPCa were established in mice. Following androgen deprivation by castration, TSGs were recovered and the presence and phenotype of cancer cells were evaluated.

Results

High-grade cancer in TSGs generated from HRPCa displayed characteristic Gleason patterns and biomarker expression. Response to androgen deprivation therapy (ADT) was as in humans, with some cases exhibiting complete pathologic regression and others showing resistance to castration. As in humans, ADT decreased cell proliferation and prostate-specific antigen expression in TSGs. Adverse pathological features of parent HRPCa were associated with lack of regression of cancer in corresponding TSGs after ADT. Castration-resistant cancer cells remaining in TSGs showed upregulated expression of androgen receptor target genes, as occurs in castration-resistant prostate cancer (CRPC) in humans. Finally, a rare subset of castration-resistant cancer cells in TSGs underwent epithelial-mesenchymal transition, a process also observed in CRPC in humans.

Conclusions

Our study demonstrates the feasibility of generating TSGs from multiple patients and of generating a relatively large number of TSGs from the same HRPCa specimen with similar cell composition and histology among control and experimental samples in an in vivo setting. The authentic response of TSGs to ADT, which has been extensively characterized in humans, suggests that TSGs can serve as a surrogate model for clinical trials to achieve rapid and less expensive screening of therapeutics for HRPCa and primary CRPC.

【 授权许可】

   
2013 Zhao et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]D’Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D: Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002, 20(23):4567-4573.
• [2]D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH: Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003, 21(11):2163-2172.
• [3]Picard JC, Golshayan AR, Marshall DT, Opfermann KJ, Keane TE: The multi-disciplinary management of high-risk prostate cancer. Urol Oncol 2012, 30(1):3-15.
• [4]Ingels A, de la Taille A, Ploussard G: Radical prostatectomy as primary treatment of high-risk prostate cancer. Curr Urol Rep 2012, 13(2):179-186.
• [5]Nishiyama T: Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer. J Steroid Biochem Mol Biol 2012, 129(3-5):179-190.
• [6]Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Billiet I, et al.: External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010, 11(11):1066-1073.
• [7]Massard C, Fizazi K: Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res 2011, 17(12):3876-3883.
• [8]Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL: Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004, 10(1):33-39.
• [9]Scher HI, Sawyers CL: Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005, 23(32):8253-8261.
• [10]Paule B, Brion N: Adjuvant treatment for high-risk operable prostate cancer. J Cancer Therapy 2010, 1:10-20.
• [11]Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281(17):1591-1597.
• [12]Gonit M, Zhang J, Salazar M, Cui H, Shatnawi A, Trumbly R, Ratnam M: Hormone depletion-insensitivity of prostate cancer cells is supported by the AR without binding to classical response elements. Mol Endocrinol 2011, 25(4):621-634.
• [13]Nauseef JT, Henry MD: Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nat Rev Urol 2011, 8(8):428-439.
• [14]Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi S, Sarkar FH: Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 2010, 5(8):e12445.
• [15]Wu Y, Rosenberg JE, Taplin ME: Novel agents and new therapeutics in castration-resistant prostate cancer. Curr Opin Oncol 2011, 23(3):290-296.
• [16]Attard G, Richards J, de Bono JS: New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 2011, 17(7):1649-1657.
• [17]Sadar MD: Small molecule inhibitors targeting the "achilles’ heel" of androgen receptor activity. Cancer Res 2011, 71(4):1208-1213.
• [18]Nacusi LP, Tindall DJ: Targeting 5alpha-reductase for prostate cancer prevention and treatment. Nat Rev Urol 2011, 8(7):378-384.
• [19]Decaudin D: Primary human tumor xenografted models (‘tumorgrafts’) for good management of patients with cancer. Anticancer Drugs 2011, 22(9):827-841.
• [20]Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J, Sidransky D: A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011, 10(8):1311-1316.
• [21]Presnell SC, Werdin ES, Maygarden S, Mohler JL, Smith GJ: Establishment of short-term primary human prostate xenografts for the study of prostate biology and cancer. Am J Pathol 2001, 159(3):855-860.
• [22]Wang Y, Revelo MP, Sudilovsky D, Cao M, Chen WG, Goetz L, Xue H, Sadar M, Shappell SB, Cunha GR, et al.: Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate 2005, 64(2):149-159.
• [23]Huss WJ, Gray DR, Werdin ES, Funkhouser WK Jr, Smith GJ: Evidence of pluripotent human prostate stem cells in a human prostate primary xenograft model. Prostate 2004, 60(2):77-90.
• [24]Staack A, Kassis AP, Olshen A, Wang Y, Wu D, Carroll PR, Grossfeld GD, Cunha GR, Hayward SW: Quantitation of apoptotic activity following castration in human prostatic tissue in vivo. Prostate 2003, 54(3):212-219.
• [25]Montecinos VP, Godoy A, Hinklin J, Vethanayagam RR, Smith GJ: Primary xenografts of human prostate tissue as a model to study angiogenesis induced by reactive stroma. PLoS One 2012, 7(1):e29623.
• [26]Zhao H, Nolley R, Chen Z, Peehl DM: Tissue slice grafts: an in vivo model of human prostate androgen signaling. Am J Pathol 2010, 177(1):229-239.
• [27]Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007, 104(3):973-978.
• [28]van Rijn RS, Simonetti ER, Hagenbeek A, Hogenes MC, de Weger RA, Canninga-van Dijk MR, Weijer K, Spits H, Storm G, van Bloois L, et al.: A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2−/− gammac−/− double-mutant mice. Blood 2003, 102(7):2522-2531.
• [29]Defosse DL, Duray PH, Johnson RC: The NIH-3 immunodeficient mouse is a model for lyme borreliosis myositis and carditis. Am J Pathol 1992, 141(1):3-10.
• [30]Mukuta T, Arreaza G, Nishikawa M, Resetkova E, Jamieson C, Tamai H, Volpe R: Thyroid xenografts from patients with Graves’ disease in severe combined immunodeficient mice and NIH-beige-nude-xid mice. Clin Invest Med 1997, 20(1):5-15.
• [31]Gray DR, Huss WJ, Yau JM, Durham LE, Werdin ES, Funkhouser WK Jr, Smith GJ: Short-term human prostate primary xenografts: an in vivo model of human prostate cancer vasculature and angiogenesis. Cancer Res 2004, 64(5):1712-1721.
• [32]Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ, et al.: Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 2002, 62(8):2220-2226.
• [33]Kron K, Liu L, Trudel D, Pethe V, Trachtenberg J, Fleshner N, Bapat B, van der Kwast T: Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer. Clin Cancer Res 2012, 18(10):2896-2904.
• [34]Guinan P, Didomenico D, Brown J, Shaw M, Sharifi R, Ray V, Shott S, Rubenstein M: The effect of androgen deprivation on malignant and benign prostate tissue. Med Oncol 1997, 14(3–4):145-152.
• [35]Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, et al.: Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009, 138(2):245-256.
• [36]Tsuji M, Murakami Y, Kanayama H, Sano T, Kagawa S: Immunohistochemical analysis of Ki-67 antigen and Bcl-2 protein expression in prostate cancer: effect of neoadjuvant hormonal therapy. Br J Urol 1998, 81(1):116-121.
• [37]Barnes EA, Kenerson HL, Jiang X, Yeung RS: Tuberin regulates E-cadherin localization: implications in epithelial-mesenchymal transition. Am J Pathol 2010, 177(4):1765-1778.
• [38]Schmalhofer O, Brabletz S, Brabletz T: E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 2009, 28(1–2):151-166.
• [39]Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, Sternberg CN, Studer UE: Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol 2009, 55(1):62-75.
• [40]Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ, et al.: Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res 2012, 72(2):527-536.
• [41]Clyne M: Prostate cancer: androgen deprivation causes EMT in the prostate. Nat Rev Urol 2012, 9(1):4.
• [42]Cespedes MV, Larriba MJ, Pavon MA, Alamo P, Casanova I, Parreno M, Feliu A, Sancho FJ, Munoz A, Mangues R: Site-dependent E-cadherin cleavage and nuclear translocation in a metastatic colorectal cancer model. Am J Pathol 2010, 177(4):2067-2079.
• [43]Armas OA, Aprikian AG, Melamed J, Cordon-Cardo C, Cohen DW, Erlandson R, Fair WR, Reuter VE: Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 1994, 18(10):979-991.
• [44]Kitagawa Y, Koshida K, Mizokami A, Komatsu K, Nakashima S, Misaki T, Katsumi T, Namiki M: Pathological effects of neoadjuvant hormonal therapy help predict progression of prostate cancer after radical prostatectomy. Int J Urol 2003, 10(7):377-382.
• [45]Geller J, Albert J: Effects of castration compared with total androgen blockade on tissue dihydrotestosterone (DHT) concentration in benign prostatic hyperplasia (BPH). Urol Res 1987, 15(3):151-153.
• [46]Nishiyama T, Hashimoto Y, Takahashi K: The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 2004, 10(21):7121-7126.
• [47]Lin CY, Lin MT, Cheng RT, Chen SH: Testosterone depletion by castration may protect mice from heat-induced multiple organ damage and lethality. J Biomed Biotechnol 2010, 2010:485306.
• [48]van Weerden WM, Bierings HG, van Steenbrugge GJ, de Jong FH, Schroder FH: Adrenal glands of mouse and rat do not synthesize androgens. Life Sci 1992, 50(12):857-861.
• [49]Keegan CE, Hammer GD: Recent insights into organogenesis of the adrenal cortex. Trends Endocrinol Metab 2002, 13(5):200-208.
• [50]Bielohuby M, Herbach N, Wanke R, Maser-Gluth C, Beuschlein F, Wolf E, Hoeflich A: Growth analysis of the mouse adrenal gland from weaning to adulthood: time- and gender-dependent alterations of cell size and number in the cortical compartment. Am J Physiol Endocrinol Metab 2007, 293(1):E139-146.
• [51]DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, et al.: Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011, 17(11):1514-1520.